Pontiki, Eleni published the artcileHistone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives, Synthetic Route of 122110-53-6, the publication is Medicinal Research Reviews (2012), 32(1), 1-165, database is CAplus and MEDLINE.
A review. Histone deacetylase (HDAC) inhibition is a recent, clin. validated therapeutic strategy for cancer treatment. HDAC inhibitors (HDACIs) block angiogenesis, arrest cell growth, and lead to differentiation and apoptosis in tumor cells. In this article, a survey of published quant. structure-activity relationships (QSARs) studies are presented and discussed in the hope of identifying the structural determinants for anticancer activity. Secondly a two-dimensional QSAR study was carried out on biol. results derived from various types of HDACIs and from different assays using the C-QSAR program of Biobyte. The QSAR anal. presented here is an attempt to organize the knowledge on the HDACIs with the purpose of designing new chem. entities with enhanced inhibitory potencies and to study the mechanism of action of the compounds This study revealed that lipophilicity is one of the most important determinants of activity. Addnl., steric factors such as the overall molar refractivity (CMR), molar volume (MgVol), the substituent’s molar refractivity (MR) (linear or parabola), or the sterimol parameters B1 and L are important. Electronic parameters indicated as σp, are found to be present only in one case. © 2010 Wiley Periodicals, Inc. Med Res Rev 32:1-165, 2012.
Medicinal Research Reviews published new progress about 122110-53-6. 122110-53-6 belongs to esters-buliding-blocks, auxiliary class Aliphatic hydrocarbon chain,Ester,Inhibitor, name is (Pivaloyloxy)methyl butyrate, and the molecular formula is C10H18O4, Synthetic Route of 122110-53-6.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics